Functional Precision Oncology in Fibrolamellar Carcinoma: Ex Vivo Identification of Therapeutic Vulnerabilities
Cancers · 27.05.2026 · 18 (11) · 1744
DOI: 10.3390/cancers18111744 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 27.05.2026. Verfasst von Sabina A Schneider und 11 weiteren Autor:innen. Beteiligte Einrichtung: Nagourney Cancer Institute, 750 East 29th Street, Long Beach, CA 90806, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fibrofighters.org, FibroFighters Foundation.
Abstract (Originalsprache)
Background
Fibrolamellar carcinoma (FLC) is a rare liver malignancy affecting adolescents. FLCs harbor a DNAJB1–PRKACA gene fusion that combines heat shock protein DNAJB1 with the catalytic subunit of protein kinase A. Surgery with systemic therapy provides 5-year survivals of 30–50%, but advanced disease remains largely incurable. Three-dimensional explants from 41 FLC patients were interrogated for drug sensitivity, resistance, and synergy against cytotoxics, targeted agents, and signal transduction inhibitors.
Methods
Sterile specimens from histologically confirmed FLC patients were analyzed by Ex Vivo Analysis of Programmed Cell Death (EVA/PCD™) in a CLIA-licensed laboratory. Following mechanical and enzymatic disaggregation, explants underwent 72 h drug exposure. LC50 values were derived from five-point dose–response curves and compared with a database of over 10,000 human tumor analyses. Synergy was assessed by combination index. In parallel, targeted metabolomic profiling was performed in five FLC patients using tandem MS/MS.
Results
Forty-one samples were analyzed. Of 24 drugs selected, tumor-cell yields were adequate for testing in 18 (75%). Single-agent activity favored vorinostat, followed by phenformin and 6-diazo-5-oxo-L-norleucine. Combinations favored gemcitabine plus oxaliplatin (GEMOX) and 5-FU plus interferon. Metabolomic analysis identified distinct signature consistent with mitochondrial dysfunction and altered polyamine metabolism.
Conclusions
The present findings are exploratory, and hypothesis-generating and should not be interpreted as evidence of clinical efficacy. Prospective clinical validation and mechanistic studies will be required to further define the therapeutic relevance of these observations in fibrolamellar carcinoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nagourney Cancer Institute, 750 East 29th Street, Long Beach, CA 90806, USA.
- Metabolomycs, Inc., 750 East 29th Street, Long Beach, CA 90806, USA.
- Gynecology Department, School of Medicine of the Federal University of São Paulo (EPM-UNIFESP), Rua Pedro de Toledo 781, São Paulo 04039-032, SP, Brazil.
- FibroFighters Foundation, 31805 Temecula Parkway #D7-512, Temecula, CA 92592, USA.
- Department of Obstetrics and Gynecology, University of California Irvine (UC Irvine), 101 The City Drive South, Orange, CA 92868, USA.
ORCID-Profile: Paulo D'Amora, Paul Kent
Förderung
- Fibrofighters.org
- FibroFighters Foundation
Zitieren
APA
Schneider, S. A., D'Amora, P., Evans, S. S., Kent, P., Stockwell, T., Bakaya, V. S., Bernard, P. J., Francisco, F. R., Torres, L., Henry, J., Silva, I. D. C. G., & Nagourney, R. A. (2026). Functional Precision Oncology in Fibrolamellar Carcinoma: Ex Vivo Identification of Therapeutic Vulnerabilities. Cancers, 18(11), 1744. https://doi.org/10.3390/cancers18111744
Vancouver
Schneider SA, D'Amora P, Evans SS, Kent P, Stockwell T, Bakaya VS, et al. Functional Precision Oncology in Fibrolamellar Carcinoma: Ex Vivo Identification of Therapeutic Vulnerabilities. Cancers. 2026;18(11):1744. doi:10.3390/cancers18111744
BibTeX
@article{Schneider2026,
author = {Schneider, Sabina A and D'Amora, Paulo and Evans, Steven S and Kent, Paul and Stockwell, Tom and Bakaya, Vikrant S and Bernard, Paula J and Francisco, Federico R and Torres, Luisa and Henry, John and Silva, Ismael D C G and Nagourney, Robert A},
title = {Functional Precision Oncology in Fibrolamellar Carcinoma: Ex Vivo Identification of Therapeutic Vulnerabilities},
journal = {Cancers},
year = {2026},
volume = {18},
number = {11},
pages = {1744},
doi = {10.3390/cancers18111744}
}
EUVIMED